Compare Stocks: ATRA, ORIC, PRLD, and CYPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.60 +0.5%	$8.96	$3.92 ▼ $19.15	$86.34M	0.1	651,531 shs	3,252 shs
CYPH Cypherpunk Technologies	$3.73 +3.3%	$1.50	$0.31 ▼ $4.02	$401.95M	0.33	5.12 million shs	5.28 million shs
ORIC Oric Pharmaceuticals	$12.99 -2.6%	$12.68	$7.23 ▼ $14.93	$1.35B	1	1.69 million shs	196,928 shs
PRLD Prelude Therapeutics	$3.96 -8.2%	$5.04	$1.15 ▼ $6.83	$315.62M	0.97	428,718 shs	152,279 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	-4.14%	-15.33%	-9.51%	-16.24%	-34.00%
CYPH Cypherpunk Technologies	-3.22%	+47.95%	+114.88%	+503.17%	+1,122.07%
ORIC Oric Pharmaceuticals	-1.26%	+6.30%	-0.97%	+40.91%	+27.19%
PRLD Prelude Therapeutics	-11.13%	-3.58%	-33.38%	+5.12%	+318.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.60 +0.5%	$8.96	$3.92 ▼ $19.15	$86.34M	0.1	651,531 shs	3,252 shs
CYPH Cypherpunk Technologies	$3.73 +3.3%	$1.50	$0.31 ▼ $4.02	$401.95M	0.33	5.12 million shs	5.28 million shs
ORIC Oric Pharmaceuticals	$12.99 -2.6%	$12.68	$7.23 ▼ $14.93	$1.35B	1	1.69 million shs	196,928 shs
PRLD Prelude Therapeutics	$3.96 -8.2%	$5.04	$1.15 ▼ $6.83	$315.62M	0.97	428,718 shs	152,279 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	-4.14%	-15.33%	-9.51%	-16.24%	-34.00%
CYPH Cypherpunk Technologies	-3.22%	+47.95%	+114.88%	+503.17%	+1,122.07%
ORIC Oric Pharmaceuticals	-1.26%	+6.30%	-0.97%	+40.91%	+27.19%
PRLD Prelude Therapeutics	-11.13%	-3.58%	-33.38%	+5.12%	+318.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.50	Moderate Buy	$9.50	10.98% Upside
CYPH Cypherpunk Technologies	2.00	Hold	$4.90	35.73% Upside
ORIC Oric Pharmaceuticals	2.80	Moderate Buy	$20.18	51.40% Upside
PRLD Prelude Therapeutics	2.50	Moderate Buy	$8.75	103.02% Upside

Current Analyst Ratings Breakdown

Latest ATRA, ORIC, PRLD, and CYPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	ORIC Oric Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$26.00
9/17/2026	PRLD Prelude Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
9/10/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1.60 ➝ $4.90
8/27/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$1.60
8/24/2026	ATRA Atara Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/19/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$0.90 ➝ $1.60
8/18/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $27.00
7/31/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$120.77M	0.71	$4.65 per share	1.84	($5.34) per share	-1.60
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	$1.83 per share	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A
PRLD Prelude Therapeutics	$22.42M	15.34	N/A	N/A	$1.09 per share	3.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	$32.69M	-$1.18	N/A	6.20	N/A	-269.42%	-79.12%	-73.01%	10/29/2026 (Estimated)
CYPH Cypherpunk Technologies	$4.82M	$0.56	6.45	N/A	N/A	N/A	-20.76%	-19.48%	N/A
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	11/12/2026 (Estimated)
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)

Latest ATRA, ORIC, PRLD, and CYPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	-$0.32	-$0.0050	-$0.32	$0.55 million	$0.63 million
8/12/2026	Q2 2026	CYPH Cypherpunk Technologies	N/A	$0.18	N/A	$0.18	N/A	N/A
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	1.98	1.98
CYPH Cypherpunk Technologies	N/A	79.19	79.19
ORIC Oric Pharmaceuticals	N/A	13.19	13.19
PRLD Prelude Therapeutics	N/A	4.07	4.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
CYPH Cypherpunk Technologies	30.46%
ORIC Oric Pharmaceuticals	95.05%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	41.20%
CYPH Cypherpunk Technologies	3.50%
ORIC Oric Pharmaceuticals	5.70%
PRLD Prelude Therapeutics	49.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	10.04 million	5.90 million	No Data
CYPH Cypherpunk Technologies	40	107.76 million	103.99 million	Optionable
ORIC Oric Pharmaceuticals	111	103.65 million	97.75 million	Optionable
PRLD Prelude Therapeutics	79	79.80 million	40.54 million	Optionable

ATRA, ORIC, PRLD, and CYPH Headlines

Recent News About These Companies

Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial

September 21 at 4:47 AM | ad-hoc-news.deA

Prelude Therapeutics (NASDAQ:PRLD) Coverage Initiated at JPMorgan Chase & Co.

September 19, 2026 | americanbankingnews.com

Prelude Therapeutics (NASDAQ:PRLD) Stock Rating Lowered by Wall Street Zen

September 19, 2026 | marketbeat.com

JPMorgan Chase & Co. Initiates Coverage on Prelude Therapeutics (NASDAQ:PRLD)

September 17, 2026 | marketbeat.com

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 11, 2026 | globenewswire.com

Prelude Therapeutics, Incorporated: Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A ...

September 10, 2026 | finanznachrichten.de

Prelude Therapeutics Receives FDA Clearance For PRT13722 IND In HR+/HER2-Breast Cancer

September 10, 2026 | rttnews.com

Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial

September 10, 2026 | finance.yahoo.com

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

September 10, 2026 | globenewswire.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Average Rating of "Hold" by Brokerages

September 6, 2026 | marketbeat.com

Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Buy at Wall Street Zen

September 6, 2026 | marketbeat.com

BlackRock Inc. Acquires Shares of 1,797,501 Prelude Therapeutics Incorporated $PRLD

September 5, 2026 | marketbeat.com

Wall Street Zen Downgrades Prelude Therapeutics (NASDAQ:PRLD) to Hold

August 29, 2026 | marketbeat.com

ADAR1 Capital Management LLC Buys Shares of 900,900 Prelude Therapeutics Incorporated $PRLD

August 26, 2026 | marketbeat.com

Prelude Therapeutics: A Prognosis After Year-Long Rally

August 23, 2026 | seekingalpha.com

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | markets.businessinsider.com

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

July 31, 2026 | zacks.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

July 17, 2026 | zacks.com

Prelude Therapeutics

July 14, 2026 | fool.com

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 10, 2026 | seekingalpha.com

Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 16, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATRA, ORIC, PRLD, and CYPH Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$8.60 +0.04 (+0.47%)

As of 10:23 AM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Cypherpunk Technologies NASDAQ:CYPH

$3.73 +0.12 (+3.32%)

As of 10:33 AM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Oric Pharmaceuticals NASDAQ:ORIC

$12.98 -0.35 (-2.59%)

As of 10:48 AM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Prelude Therapeutics NASDAQ:PRLD

$3.96 -0.36 (-8.24%)

As of 10:46 AM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATRA, ORIC, PRLD, and CYPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATRA, ORIC, PRLD, and CYPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATRA, ORIC, PRLD, and CYPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATRA, ORIC, PRLD, and CYPH Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Cypherpunk Technologies NASDAQ:CYPH

Oric Pharmaceuticals NASDAQ:ORIC

Prelude Therapeutics NASDAQ:PRLD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATRA, ORIC, PRLD, and CYPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATRA, ORIC, PRLD, and CYPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATRA, ORIC, PRLD, and CYPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATRA, ORIC, PRLD, and CYPH Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Cypherpunk Technologies NASDAQ:CYPH

Oric Pharmaceuticals NASDAQ:ORIC

Prelude Therapeutics NASDAQ:PRLD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools